European Primary Care Cardiovascular Society

Triglyceride-rich lipoproteins as residual CV risk in patients on statins

10' education - May 8, 2022 - Prof. Alberto Zambon, MD, PhD - Padua, Italy


Show transscript

Video navigation menu

  • Residual CV risk 0:25
  • Focus on all atherogenic lipoproteins 3:11
  • Clinical evidence of relationship between TG-rich lipoproteins and CV risk 6:12
  • Conclusions 9:32

Educational information

This presentation by Alberto Zambon is part of a series titled "CV risk reduction beyond statin therapy: Exploring the role of Icosapent ethyl".


Alberto Zambon is Associate Professor of Medicine at the Department of Medicine at the University of Padua School of Medicine in Italy.


This recording was independently developed under auspices of EPCCS. The views expressed in this recording are those of the individual presenter and do not necessarily reflect the views of EPCCS.


Funding for this educational program was provided by an unrestricted educational grant received from Amarin.

The information and data provided in this program were updated and correct at the time of the program development, but may be subject to change.

Share this page with your colleagues and friends: